Xencor Inc

The company is a clinical-stage biopharmaceutical firm focused on discovering and developing engineered antibody therapeutics for patients with cancer and autoimmune diseases. It leverages proprietary protein engineering technologies to design modular Fc domains and multi-specific antibody formats under the XmAb platform, which feature improved half-life, cytotoxic activity, and targeted immune mechanisms. Its pipeline includes wholly owned clinical-stage candidates such as XmAb819 and XmAb541 for oncology indications, and XmAb942, plamotamab, and XmAb657 for autoimmune and inflammatory conditions. The company targets patients with serious unmet medical needs and serves commercial biopharmaceutical partners through collaborative research, product licensing, and platform technology access agreements.

The organization conducts clinical trial programs across Phase 1 and Phase 2 stages and advances partnered candidates through licensing alliances with global reach. Partnered programs utilizing its proprietary technology have produced three commercialized medicines marketed internationally, along with multiple candidates in Phase 2 and Phase 3 development worldwide. The provided text does not disclose the company's founding year, website address, or headquarters location.

Summary of the business section of Xencor's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 260 full-time employees, of which 212 were engaged in research and development activities, and 48 were engaged in business development, information systems, facilities, human resources, or administrative support.”